InsidersTradesSigma
Follow the NEPHROS INC stock price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, NEPHROS INC has logged 39 public disclosures. Market capitalisation: €49.8m. The latest transaction was reported on 20 August 2026 (Levée d'options). Among the most active insiders: Amron Arthur H. Every trade is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€218,562
9 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate NEPHROS INC Buy (bullish), based on 3 analysts. Average price target: US$6.25.
51Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 13,003 of 29,062 companies
54.7
score / 100
Value37
Quality72
FCF yld3.3%
Earn yld2.4%
EV/EBITDA37.5x
ROE16%
Gross mgn62%
Net mgn6.4%
Debt/EBITDA0.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 20 August 2026
Declarations39 total
812 shares@ US$3.60Common StockSEC:0001398344-26-015086:0
2,418 shares0Common StockSEC:0000914190-26-000110:0
3,574 shares0Common StockSEC:0000914190-26-000098:0
120,000 shares@ US$1.4451.1% of flowCommon StockSEC:0000914190-26-000053:0
68,861 shares@ US$1.71100.0% of flowCommon StockSEC:0000914190-26-000052:0
3,610 shares0Common StockSEC:0000914190-26-000042:0
8,036 shares0Common StockSEC:0000914190-25-000040:0
5,391 shares0Common StockSEC:0000914190-25-000039:0
1,622 shares0Common StockSEC:0000914190-25-000041:0
22,418 shares0Common StockSEC:0001062993-25-000264:0
33,241 shares0Common StockSEC:0001062993-25-000233:0
2,000 shares@ US$2.220720.7% of flowCommon StockSEC:0001062993-24-011498:0
Canonical exit: 26 Aug 2024 (T+90)
50,000 shares@ US$2.24172.1% of flowCommon StockSEC:0001062993-24-010486:0
Canonical exit: 14 Aug 2024 (T+90)
7,000 shares@ US$2.447179.3% of flowCommon stockSEC:0001048462-24-000011:0
Canonical exit: 10 Jun 2024 (T+90)
91,463 shares0Common StockSEC:0001048462-24-000012:0
9,291 shares0Common StockSEC:0001062993-23-022642:0
9,291 shares0Common StockSEC:0001062993-23-022643:0
9,291 shares0Common StockSEC:0001062993-23-022644:0
14,294 shares0Common StockSEC:0001062993-23-022645:0
18,000 shares@ US$2.202625.8% of flowCommon StockSEC:0001062993-23-022326:0
Canonical exit: 6 Mar 2024 (T+90)
99 shares@ US$1.500.1% of flowCommon StockSEC:0001062993-23-016523:0
Canonical exit: 12 Nov 2023 (T+90)
1,901 shares@ US$1.68692.1% of flowCommon StockSEC:0001062993-23-016523:1
Canonical exit: 13 Nov 2023 (T+90)
42,481 shares0Common StockSEC:0001062993-23-000720:0
8,402 shares0Common StockSEC:0001062993-23-000717:0
27,613 shares0Common StockSEC:0001062993-23-000719:0
25 of 39 declarations
关于 NEPHROS INC
Nephros, Inc.（股票代码：NEPH）在美国纳斯达克市场上市，是一家专注于医疗和商业应用水过滤解决方案的专业公司。对于法语投资者而言，该公司处于医疗技术、受监管的过滤产品和关键基础设施的交汇点，而非传统的“纯粹”医疗技术公司。其核心价值主张是水安全：减少污染物并支持医院、透析中心和水质对运营至关重要的商业设施等敏感环境中的卫生要求。([nephros.com](https://www.nephros.com/investors/?utm_source=openai)) Nephros 最初由哥伦比亚大学的健康专业人士、科学家和工程师创立，历史重点是终末期肾病治疗的技术和产品。随着时间的推移，该公司发展成为一家更广泛的水技术企业。根据公司披露，其总部、研发、制造和分销职能集中在新泽西州，在南奥兰治和惠帕尼设有工厂。这种布局使公司能够更严格地控制产品开发和交付，同时保持组织相对精简。([fintel.io](https://fintel.io/doc/sec-nephros-inc-1196298-10k-2025-march-24-20171-4878?utm_source=openai)) 从商业模式的角度来看，Nephros 通过两个主要终端市场销售过滤产品和相关解决方案：医疗和商业。在医疗应用中，该公司服务于感染控制和透析相关的用例，其中可靠性和法规遵从性至关重要。在商业应用中，其产品面向需要持续水质管理以确保安全、设备保护和运营连续性的客户。管理层还强调结合产品、服务和教育的综合方法，这表明其战略旨在建立重复关系和客户保留，而不是仅仅依赖一次性产品销售。([nephros.com](https://www.nephros.com/investors/?utm_source=openai)) 竞争定位是一家专注的利基市场参与者。Nephros 并非全球巨头，但它通过专注于关键环境的水过滤、监管定位以及为高风险环境设计的产品集来区分自己。最近的披露表明，该战略一直在取得进展：在2025年全年和2026年初，该公司报告了强劲的收入增长、创纪录的程序化销售和不断扩大的活跃站点数量。它还在2025年推出了新的S100在线微滤器，管理层称其将微滤和超滤之间的产品组合进行了扩展。([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-strong-third-quarter-financial-results-achieving-highest-level?utm_source=openai)) 对于投资者而言，NEPH 提供了防御性终端市场敞口、监管壁垒以及与医疗保健和商业环境中水质需求相关的增长潜力。与此同时，该公司最近关于关税和供应链状况的评论突显了其面临投入成本压力和执行风险。总体而言，Nephros 仍然是一家在纳斯达克上市的小盘股公司，拥有专业的特许经营权和近期运营势头，这可能支持投资者的兴趣，前提是投资者接受小型利基工业医疗保健企业典型的风险。([nasdaq.com](https://www.nasdaq.com/press-release/nephros-announces-fourth-quarter-and-record-fiscal-year-2025-financial-results-2026?utm_source=openai))
